MM 45289, a potent glycopeptide antibiotic which interacts weakly with diacetyl-L-lysyl-D-alanyl-D-alanine.
- 1 January 1990
- journal article
- research article
- Published by Japan Antibiotics Research Association in The Journal of Antibiotics
- Vol. 43 (5) , 550-555
- https://doi.org/10.7164/antibiotics.43.550
Abstract
MM 45289 (A82846A, eremomycin), a glycopeptide antibiotic of the vancomycin type, was confirmed to have improved antibacterial activity over vancomycin. However its affinity (Ka) for the target site peptide mimetic diacetyl-L-lysyl-D-alanyl-D-alanine (DALAA) was 23-fold lower. Concentrations of DALAA required to reverse the antibacterial activity of MM 45289 were in the order of 10 to 50-fold higher than for vancomycin. These results have implications for both mode of action studies and mechanism-based screening strategies for this class of antibiotic.This publication has 3 references indexed in Scilit:
- Function of the amino sugar and N-terminal amino acid of the antibiotic vancomycin in its complexation with cell wall peptidesJournal of the American Chemical Society, 1988
- Glycopeptide antibiotics: A mechanism-based screen employing a bacterial cell wall receptor mimetic.The Journal of Antibiotics, 1986
- A membrane enzyme from Staphylococcus aureus which catalyzes transpeptidase, carboxypeptidase, and penicillinase activitiesJournal of Biological Chemistry, 1978